Indivior Pharmaceuticals, Inc. (INDV) FY2026 YTD Q3 Statement of Cash Flows
Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)
Statement of Cash Flows
Swipe to see the full flow
Chart details
Indivior Pharmaceuticals, Inc. cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026
Cash flows for Jan 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.
- Beginning cash on Dec 31, 2025
- 195,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- Operating activities
- 317,000,000 US dollars. Net cash provided. The remaining amount is calculated by subtracting the other displayed items from the operating total. The filing's tagged operating lines do not add up to the operating total; this is the difference. It may combine inflows and outflows.
- Net income
- 348,000,000 US dollars
- Depreciation and amortization
- 5,000,000 US dollars
- Amortization of right-of-use assets
- 4,000,000 US dollars
- Stock-based compensation
- 28,000,000 US dollars
- Impairment of tangible and intangible assets
- 8,000,000 US dollars
- Loss on debt extinguishment
- 18,000,000 US dollars
- Unrealized loss on equity investments
- 0 US dollars
- Deferred income taxes
- 35,000,000 US dollars
- Impact from foreign exchange movements
- 4,000,000 US dollars
- Amortization of debt issuance costs
- 1,000,000 US dollars
- Other adjustments, net
- 0 US dollars
- Accounts receivable
- negative 19,000,000 US dollars
- Current inventories
- 4,000,000 US dollars
- Other current and noncurrent assets
- negative 20,000,000 US dollars
- Accrued legal and settlement expenses
- negative 38,000,000 US dollars
- Other current and noncurrent liabilities
- negative 62,000,000 US dollars
- Remaining operating cash flows, net (calculated)
- 1,000,000 US dollars
- Investing activities
- negative 41,000,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the investing total. The filing's tagged investing lines do not add up to the investing total; this is the difference. It may combine inflows and outflows.
- Purchases of property and equipment
- negative 41,000,000 US dollars
- Purchases of in-process research and development and intangible assets
- 0 US dollars
- Purchases of investments in debt securities
- negative 12,000,000 US dollars
- Sales and maturities of debt securities
- 13,000,000 US dollars
- Remaining investing cash flows, net (calculated)
- negative 1,000,000 US dollars
- Financing activities
- negative 166,000,000 US dollars. Net cash used.
- Proceeds from the issuance of common stock
- 0 US dollars
- Cash paid for repurchases of common stock
- negative 302,000,000 US dollars
- Proceeds from debt, net
- 489,000,000 US dollars
- Repayments of debt
- negative 333,000,000 US dollars
- Other
- 6,000,000 US dollars
- Transaction costs related to debt refinancing
- negative 5,000,000 US dollars
- Settlement of equity awards
- negative 21,000,000 US dollars
- Operating adjustment reconciliation
- 139,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
- financing gross reconciliation
- 661,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- investing displayed reconciliation
- 54,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
- Exchange-rate effect
- 0 US dollars
- Ending cash on Sep 30, 2026
- 305,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- Cash sources and uses
- 512,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- Net cash change
- 110,000,000 US dollars. Ending cash minus beginning cash.
- Cash flow / Net income
- 0.91×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
- Operating cash flow
- 317,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
- Cash purchases of property, plant and equipment
- 41,000,000 US dollars. These cash purchases are already included in investing activities above.
- Free cash flow
- 276,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.
Chart connections
- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net income exceeds operating cash. The diagram allocates $317.00M of net income directly to operating cash and $31.00M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 317,000,000 US dollars minus 41,000,000 US dollars equals 276,000,000 US dollars.

Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!
